Although thrombolytic therapy has been a major advance in the treatment of acute ST-segment elevation myocardial infarction (MI), new thrombolytic agents have been unable to improve early reperfusion. Because aspirin has been shown to be a very effective adjunctive agent in patients with acute MI, it has been hypothesized that the use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors combined with thrombolytic agents would lead to more effective platelet inhibition and improved angiographic and clinical efficacy. Emerging experimental and clinical data, including the Thrombolysis in Myocardial Infarction (TIMI)-14 trial, suggest that combining GP IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk. Thus, given the strong clinical and physiologic rationale, clinical investigation in patients with acute ST-segment elevation MI is currently focused on combining GP IIb/IIIa receptor inhibitors with reduceddose fibrinolytic agents in acute MI.
Introduction
While thrombolytic therapy has proven to be a major advance in the treatment of patients with acute myocardial infarction (MI), 1, 2 current thrombolytic regimens have several limitations: (1) failure of initial reperfusion, 3, 4 (2) inadequate perfusion with delayed Thrombolysis in Myocardial Infarction (TIMI) grade 2 flow, 3, 4 (3) imperfect myocardial perfusion, 5 and (4) infarct-related artery (IRA) reocclusion/ reinfarction in significant percentages of patients. 4, 6 Even with the second-and third-generation plasminogen activators, rates of TIMI grade 3 flow in the IRA have remained at approximately 60%. 7, 8 Because these problems are associated with increased subsequent mortality 5, 6, 9 and because platelets play a central role in coronary thrombosis, especially failed reperfusion, reocclusion, and reinfarction, attention has turned to the glycoprotein (GP) IIb/IIIa receptor inhibitors as a means of improving current reperfusion regimens. 10 
Mechanisms of Thrombolytic Resistance and Reocclusion
Rupture or erosion of a lipid-rich atherosclerotic plaque exposes the subendothelial plaque components to circulating blood. 11, 12 Platelet adhesion and aggregation at this site lead to the formation of a thrombus that can cause myocardial ischemia or infarction. Recent angioscopic studies have shown that a substantial portion of an occlusive coronary thrombus (which previously had been thought to consist only of fibrinrich "red" clot) is made up of platelets (the so-called "white" clot). 13 These findings also have been found in pathologic studies of ruptured plaques. 14, 15 Platelet-rich thrombi are more resistant to fibrinolytic therapy than are thrombi composed predominantly of fibrin and erythrocytes. 16 Lack of initial reperfusion, which could be termed "thrombolytic resistance," occurs due to several mechanisms (Table  I) : (1) Fibrinolytic agents act only on the fibrin portion of the thrombus, leaving activated platelets as a source of rethrombosis; (2) platelets elicit plasminogen activator inhibitor-1 (PAI-1), which inhibits the action of the thrombolytic agent, and platelets also release other agents such as thromboxane A2, which causes local vasoconstriction; 17, 18 (3) lysis of clotbound fibrin exposes clot-bound thrombin, which remains catalytically active and can cleave fibrinogen to fibrin, facilitating rethrombosis. 19 In addition, thrombosis can stimulate further thrombin production and activation of platelets; 20 thrombolytic therapy also has a direct platelet-activating effect, leading to increased levels of thromboxane A2 and platelet-activating factor (PAF). 18 , 21 The presence of aspirin does not abolish the platelet-activating effect of fibrinolytic therapy. 17, 18 In summary, fibrinolysis promotes platelet activation and, therefore, actually creates an environment that may lead to subsequent rethrombosis and/or reocclusion.
Aspirin
Coadministration of aspirin addresses some of the limitations of thrombolytic agents. Aspirin has been shown to decrease the risks of IRA reocclusion, 22 reinfarction, 2, 23-25 and mortality, 2 benefits additive to those achieved by thrombolytic therapy. These clinical observations highlight the pathophysiologic synergism of aspirin and thrombolytic therapy, which exists because each agent targets a separate part of the thrombus. Although aspirin is a relatively weak antiplatelet agent, its dramatic clinical benefits have increased awareness of the central role that platelets play in the thrombus formation process and rethrombosis after thrombolytic therapy. This has spurred the development of agents that have a more direct effect on platelet aggregation, such as the GP IIb/IIIa receptor antagonists, which bind directly to the receptors on the platelet surface that are responsible for platelet aggregation.
Platelets and Acute Myocardial Infarction
Acute MI is usually caused by the rupture or ulceration of an atherosclerotic plaque. The subendothelial matrix (i.e., collagen and tissue factor) is exposed to the circulating blood, and platelets mediate the "primary hemostasis" at the site of a ruptured plaque (Fig. 1) . The first step is platelet adhesion via the GP Ib receptor, as well as via von Willebrand factor. This is followed by platelet activation, which leads to (1) a shape change in the platelet (from a smooth discoid shape to a spiculated form-this increases the surface area upon which thrombin generation can occur); (2) degranulation of the alpha and dense granules, thereby releasing thromboxane A2, serotonin, and other platelet aggregatory and chemoattractant agents; and (3) expression of GP IIb/IIIa receptors on the platelet surface in an "activated" state such that they can bind fibrinogen. The final step is platelet aggregation, that is, the formation of the platelet plug. Fibrinogen (or von Willebrand factor) binds to the activated GP IIb/IIIa receptors of platelets, thereby creating a growing platelet aggregate.
GP IIb/IIIa Receptor Inhibition
Fibrinogen and von Willebrand factor, as well as fibronectin and vitronectin, bind to platelet GP IIb/IIIa receptors via an arginine-glycine-aspartic acid (RGD) sequence. Although many agonists can activate platelets, the binding of adhesive proteins to integrins on adjacent platelets represents the final common pathway in the biological process of platelet aggregation. Thus, profound suppression of platelet aggregation may be achieved by direct blockade of the GP IIb/IIIa receptor that extends beyond the capabilities of aspirin, ticlopidine, and clopidogrel.
It was initially demonstrated in 1983 that GP IIb/IIIa receptor blockade by the murine monoclonal antibody 10E5 completely inhibited platelet aggregation induced by adenosine diphosphate, thrombin, and epinephrine. 26 Removal of the Fc fragment of a similar antibody, 7E3, and subsequent recombination of the Fab fragment with constant regions of human immunoglobulin resulted in the chimeric antibody c7E3 Fab, later named abciximab. Several peptide and pharmacologic GP IIb/IIIa receptor inhibitors, with varying affinity for the target integrin, were subsequently developed.
These nonantibody agents work by mimicking the RGD sequence on fibrinogen to inhibit the platelet GP IIb/IIIa receptor. Abciximab binds to the IIb/IIIa receptor and to a broader group of integrins, such as the ␣v␤3 (vitronectin) receptor, which appears to be important in neointimal proliferation. In addition, abciximab has been shown to inhibit thrombin generation by tissue factor, most likely due to its dual blockade of the GP IIb/IIIa and ␣v␤3 receptors. 27 
Clinical Experience with GP IIb/IIIa Receptor Inhibitors Percutaneous Coronary Intervention
Extensive research has been conducted on the prophylactic use of GP IIb/IIIa receptor blockers in a spectrum of patients undergoing percutaneous coronary intervention (PCI). The first agent to be studied was abciximab, in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial. For patients undergoing high-risk angioplasty or atherectomy, treatment with abciximab was associated with a significant 35% reduction in major ischemic events at 30 days. 28 This benefit has been shown to be sustained at 3 years. 29 Clinical benefit was also seen in the Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade (EPILOG) trial of high-and low-risk patients who received abciximab 30 and in the Integrilin to Minimize Platelet Aggregation and Prevent Coronary Thrombus (IMPACT)-II trial of eptifibatide, which also comprised patients from all risk strata, 31 patients with refractory unstable angina treated with abciximab, 32, 33 patients with ongoing or recent acute coronary syndromes who received tirofiban, 34 patients undergoing coronary stenting, 35 and patients undergoing "primary PCI" for acute ST-segment elevation MI. [36] [37] [38] 
Mortality Benefit
The most recent data in the PCI setting come from the Evaluation of IIb/IIIa Platelet Inhibitor for Stenting (EPISTENT) trial that compared stenting plus placebo with stenting plus abciximab and balloon angioplasty plus abciximab. The addition of abciximab led to a > 50% reduction in death, MI, and urgent revascularization at 30 days for the stenting plus abciximab group compared with the stenting plus placebo group (absolute reduction of 5.5%). 35 At 1 year, there was a mortality benefit for abciximab: patients undergoing elective stenting had a mortality of 2.4% versus 1.0% (p = 0.03) for patients receiving abciximab plus stenting. 39 These 1-year data are the only data from a single trial demonstrating a mortality benefit for the GP IIb/IIIa receptor inhibitor class. In addition, this benefit emerged over time, a phenomenon seen in the other trials of abciximab.
There is now a paradigm shift in the understanding of the benefit of IIb/IIIa receptor inhibitors. These agents inhibit platelets, increase resolution of coronary thrombus, improve coronary flow, thus preventing early recurrent ischemic events (MI or refractory ischemia/urgent revascularization). The recent data now suggest that these benefits translate into a late mortality benefit. These new data emphasize the importance of effective platelet inhibition in these syndromes.
Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction
Glycoprotein IIb/IIIa receptor inhibitors also have been shown to be of benefit in the initial treatment of unstable angina and non-ST-segment elevation MI. In the Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study, patients with unstable angina or non-ST-segment elevation MI who received tirofiban, heparin, and aspirin had reduced rates of death, MI, or refractory ischemia compared with patients who received heparin and aspirin alone at 7 days (12.9 vs. 17.9%; p = 0.004) and at 30 days (18.5 vs. 22.3%; p = 0.03). 40 In the PRISM trial, tirofiban plus aspirin was compared with heparin plus aspirin in patients with unstable angina; tirofiban was associated with a 32% reduction in the composite endpoint of death, MI, or refractory ischemia at 48 h (3.8 vs. 5.6%; p = 0.01). 41 In addition, the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial, which studied patients with unstable angina, showed a significant reduction in the risk of death or MI at 30 days with eptifibatide compared with placebo (15.7% for the placebo group vs. 14.2% for the eptifibatide group; p = 0.04). 42 Abciximab and lamifiban are each currently being tested in large phase III trials in patients with unstable angina and non-ST-segment elevation MI: abciximab in the Global Use of Strategies to Open Occluded Arteries (GUSTO)-IV trial and lamifiban in the Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network (PARAGON)-B trial.
Thrombolytic Therapy in Combination with GP IIb/IIIa Receptor Inhibitors
Combining GP IIb/IIIa receptor inhibitors with thrombolytic therapy is the subject of current investigation. Preclinical studies were performed with this combination that first evaluated accelerated reperfusion time and reduction of the risk of reocclusion. 43, 44 These studies have led to several clinical trials.
Full-Dose Thrombolytic Therapy plus GP IIb/IIIa Receptor Inhibition

TAMI-8:
The first trial to evaluate GP IIb/IIIa receptor blockade with fibrinolytic therapy, the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI)-8 pilot study, 45 established the clinical feasibility of the combined treatment approach. After receiving a full-dose tissue plasminogen activator (t-PA) plus heparin and aspirin, patients received incremental doses of m7E3, a murine monoclonal antibody to the GP IIb/IIIa receptor. A consistent dose-dependent increase in platelet aggregation was observed, and a clear relationship between GP IIb/IIIa receptor occupancy and extent of platelet in-hibition was established. 45 The rate of major hemorrhage was not increased, and a dosage associated with 80 to 90% platelet inhibition was identified for further study.
IMPACT-AMI:
Results of the combination of eptifibatide and t-PA were reported from the Integrilin to Manage Platelet Aggregation and Combat Acute Myocardial Infarction (IMPACT-AMI) trial, which administered the two agents simultaneously. 46 Patients who received the highest dose of eptifibatide showed a significantly increased rate of TIMI grade 3 IRA flow on angiography at 90 min (66%, compared with 39% in the placebo group; p = 0.006) (Fig. 2) . 46 No differences were seen in the rates of major or minor bleeding complications, including intracranial hemorrhage (ICH). It was noted subsequently, however, that the dosages of eptifibatide used achieved only 50 to 60% platelet inhibition.
Streptokinase-Eptifibatide Trial: A subsequent trial was performed combining full-dose streptokinase with ascending dosages of eptifibatide. 47 In the double-blind, placebo-controlled pilot study involving 181 patients with acute MI, streptokinase (1.5 MU/h) was combined with eptifibatide (a 180 µg/kg bolus followed by infusions of 0.75, 1.33, or 2.0 µg/kg/ min for 24 h) without heparin. TIMI grade 3 flow in the IRA at 90 min was achieved by 53, 44, and 52% of patients randomized to the three dosage levels of eptifibatide, respectively, compared with 38% of patients in the placebo group (Fig. 2) . 47 Rates of TIMI grade 2 or 3 flow also tended to be higher in patients treated with eptifibatide, 75, 73, and 88%, respectively, compared with 65% in patients treated with placebo.
An increased incidence of bleeding, most often at the site of arterial puncture, was associated with increasing dosages of continuous infusion of eptifibatide. Rates of severe bleeding were 9, 9, and 15%, respectively, compared with 0% for placebo, which led to premature discontinuation of the highest dose of eptifibatide. There were no occurrences of ICH.
PARADIGM:
The Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial compared different lamifiban dosage levels with placebo in 353 patients presenting within 12 h of acute MI symptom onset. Patients received aspirin and heparin and either t-PA or streptokinase at standard doses. 48 Lamifiban was associated with improved myocardial reperfusion as measured by early resolution of ST-segment elevation. However, no difference in the composite clinical endpoint was noted.
Lamifiban was associated with increased rates of gastrointestinal, coronary bypass-related, and catheterization accesssite bleeding complications.
In summary, the strategy of concomitant full-dose thrombolytic therapy and full-dose GP IIb/IIIa receptor inhibition has been a difficult one to balance efficacy and safety, and attention has turned to combining full-dose GP IIb/IIIa receptor inhibitors with reduced doses of thrombolytic agents.
Reduced-Dose Thrombolytic Therapy plus GP IIb/IIIa Receptor Inhibition
The combination of a reduced-dose thrombolytic agent and a GP IIb/IIIa receptor inhibitor is being tested in the TIMI-14 trial using t-PA, streptokinase, and reteplase and in the GUSTO-IV pilot trial Strategies for Patency Enhancement in the Emergency Department (SPEED) trial using reteplase.
TIMI-14:
The international TIMI-14 trial dose-ranging phase enrolled 888 patients with MI characterized by ST-segment elevation who met standard eligibility criteria. 49 The patients were randomized within 12 h of symptom onset to one of four reperfusion regimens (each encompassing several dosage levels): (1) standard-dose t-PA alone (the control arm), (2) reduced-dose t-PA plus abciximab, (3) reduced-dose streptokinase plus abciximab, or (4) abciximab alone. All patients received aspirin and heparin. The initial heparin dosage was a 70 U/kg bolus and a 15 U/kg/h infusion in the t-PA control arm, and a 60 U/kg bolus with a 7 U/kg/h infusion in the arms that included abciximab.
Abciximab alone was associated with 90 min TIMI grade 3 flow rates in 32% of patients (similar to the historic value seen with streptokinase) and 90 min patency in 48% of patients. 49 The combination of streptokinase and abciximab produced only modest improvement in early TIMI grade 3 flow. TIMI grade 3 flow at 90 min was achieved in 42% of patients in the 0.5 MU group, 39% of patients in the 0.75 MU group, and 47% of patients in the 1.25 MU group. The 1.5 MU regimen, plus abciximab, was discontinued after four of six patients developed a major hemorrhage and one of whom developed an ICH.
The dose-ranging evaluation with t-PA found that the best angiographic results were obtained using a 50 mg dose given as a 15 mg bolus and a 35 mg infusion over 60 min. At 90 min, TIMI grade 3 flow was achieved in 77% of patients compared with 62% for t-PA alone (p = 0.01) (Fig. 3) . 49 Overall patency of the IRA was achieved in 94% of patients with the combination of abciximab and t-PA compared with 78% for t-PA (p = 0.09). An even greater difference was observed at 60 Major hemorrhage rates were similar among the t-PA-plusabciximab and control groups, approximately 6% in each. In-hospital mortality was similar among all groups, ranging from 3 to 5%.
Thus, the addition of the GP IIb/IIIa receptor inhibitor abciximab to 50 mg of t-PA was able to increase the rate of TIMI grade 3 flow at 60 min by an absolute difference of 29%, representing a relative 67% improvement over standard therapy. At 90 min, the addition of the GP IIb/IIIa receptor inhibitor improved TIMI grade 3 flow by an absolute difference of 15% (a relative 25% improvement).
The TIMI-14 trial also included an arm evaluating the reteplase-abciximab combination in varying doses. Results thus far have been promising.
These results indicate that the combination of GP IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy appears to be a promising new regimen for enhancing both the speed and extent of reperfusion in patients with MI characterized by acute ST-segment elevation.
SPEED: Because of reteplase's bolus dosing, it was the lytic of choice for this pilot trial of GUSTO-IV. Rather than an infusion, reteplase is given as a double-bolus injection, which gives unprecedented dosing flexibility in patients who may later go on to the catheterization laboratory. Because one bolus dose is given upon symptom presentation, there is no commitment made to the second bolus injection, allowing immediate lysis but not precluding later PCI if that is required. Ultimately, this allows the clinical practice team more options for patient treatment and encourages tailored therapy to optimize outcomes. Additionally, when combination therapy is administered, traditionally there are a number of infusions being given simultaneously. With reteplase's bolus dosing, one of these infusions is eliminated.
In fact, results from the recent Plasminogen Activator Coronary Angioplasty Trial (PACT) indicated that patients treated with t-PA had significant improvement in vessel patency before undergoing angioplasty, with no adverse effect on procedural safety or outcome. 50 The PACT study evaluated patients with acute MI presenting within 6 h and randomized patients to either a 50 mg t-PA bolus or placebo.
Preliminary results from the SPEED trial similarly demonstrated improvements in early TIMI grade 3 flow with reteplase, 51 indicating that the combination of low-dose fibrinolytic therapy with reteplase appears to be a potentially promising new regimen for improving both the speed and extent of thrombolysis in patients with acute MI. Treatment arms evaluated in the "facilitated PCI" segment of SPEED were abciximab alone, abciximab plus reteplase (5 U + 5 U), and reteplase alone. The combination of abciximab and reteplase had the highest rate of TIMI grade 2 or 3 flow, 76%, compared with 73% for reteplase alone and 52% for abciximab alone. Postprocedural success (defined as < 50% diameter stenosis with TIMI grade 3 flow) for the three groups was 88% for the abciximab plus reteplase combination, compared with 85% for reteplase alone and 95% for abciximab alone.
Other experience: A number of other ongoing trials are exploring further the potential role of GP IIb/IIIa receptor inhibitors with reduced-dose thrombolytic therapy, and larger phase III trials are planned. It is hoped that these trials will help define a new era of myocardial reperfusion therapy of "true thrombolysis," that is, lysis and inhibition of the platelet, thrombin, and fibrin components of occlusive thrombi.
Safety
A major concern with all regimens of thrombolytic therapy is bleeding, particularly ICH. Fortunately, GP IIb/IIIa receptor inhibitors generally have a low risk of ICH when used alone, and no apparent increase compared with aspirin and heparin in the major trials. 28, 30, 31, 34, 35, 40, 41, 48, 49 The risk of ICH when combined with thrombolytic therapy may be due largely to the risk from the latter agent, but larger trials are needed to define the exact rate.
However, it appears that the third component of the regimen, heparin, also may modulate the risk of ICH with thrombolytic therapy. Reduced doses of heparin have been found to be associated with lower rates of ICH in several trials, including TIMI 9A/B, 52, 53 GUSTO IIA/B, 54, 55 TIMI 10B, 7, 56 and Assessment of the Safety of a New Thrombolytic (ASSENT)-I. 56, 57 Similarly, using reduced doses of heparin leads to lower rates of hemorrhage with GP IIb/IIIa receptor inhibitors, as seen in the EPIC versus EPILOG trials. Thus, use of lower doses of heparin and careful monitoring of the level of anticoagulation help avoid bleeding complications in patients receiving GP IIb/IIIa receptor inhibitors. The dose of adjunctive heparin also appears to influence bleeding with either fibrinolytic agents 7, 56 or GP IIb/IIIa receptor inhibitors. 28, 30 It is hoped that the combination of reduced-dose fibrinolytic therapy plus a GP IIb/IIIa receptor inhibitor and low-dose heparin will be associated with a potentially lower rate of ICH than are current regimens. 
Conclusion
There is a strong rationale, both clinical and physiologic, for combining the potent GP IIb/IIIa receptor inhibitors with fibrinolytic agents in patients with acute ST-segment elevation MI. Current therapies need enhancement to achieve early reperfusion and decrease risk of reocclusion. Aspirin is a relatively weak platelet inhibitor yet has dramatic clinical benefits. GP IIb/IIIa receptor inhibitors have been shown to improve outcomes with a very low rate of ICH in other forms of acute coronary syndromes. It is hypothesized that the combination of GP IIb/IIIa receptor inhibitors and reduced-dose thrombolytic therapy will increase early and long-term patency rates and consequently survival, without increasing bleeding complications. Encouraging results have been observed in the dose-ranging trials to date, and the clinical benefits will be assessed in large-scale randomized trials. Although the improved TIMI 3 flow rates observed with this combination is progress, the greatest effects expected (on microvascular flow, reocclusion, inflammation, and mortality) will be evaluated in future phase II trials and phase III trials.
